• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点抑制剂在非小细胞肺癌(NSCLC)治疗中的应用:路在何方?

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?

机构信息

Laboratory of Clinical Biochemistry, 'Attikon' University General Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.

First University Department of Respiratory Medicine, 'Sotiria' Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

出版信息

Int J Mol Sci. 2024 Jun 7;25(12):6309. doi: 10.3390/ijms25126309.

DOI:10.3390/ijms25126309
PMID:38928013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11203558/
Abstract

Lung cancer has been established as the second most common cancer worldwide (most common cancer in men and second most common cancer in women) and as the leading cause of cancer morbidity among neoplasms [...].

摘要

肺癌已被确定为全球第二大常见癌症(男性中最常见的癌症,女性中第二常见的癌症),也是肿瘤中癌症发病率的主要原因[...]。

相似文献

1
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?免疫检查点抑制剂在非小细胞肺癌(NSCLC)治疗中的应用:路在何方?
Int J Mol Sci. 2024 Jun 7;25(12):6309. doi: 10.3390/ijms25126309.
2
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌:合理选择。
Immunotherapy. 2022 Feb;14(2):155-167. doi: 10.2217/imt-2021-0014. Epub 2021 Dec 6.
3
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.国家免疫治疗登记处人群水平晚期非小细胞肺癌的检查点抑制剂的疗效。
Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28.
4
Immunotherapy in advanced non-small-cell lung cancer with mutations.携带 突变的晚期非小细胞肺癌的免疫治疗。
Immunotherapy. 2020 Nov;12(16):1195-1207. doi: 10.2217/imt-2020-0148. Epub 2020 Sep 27.
5
Immune checkpoint inhibition in early-stage non-small cell lung cancer.免疫检查点抑制在早期非小细胞肺癌中的应用。
Lung Cancer. 2024 Jul;193:107855. doi: 10.1016/j.lungcan.2024.107855. Epub 2024 Jun 14.
6
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
7
Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?转移性非小细胞肺癌的免疫疗法:真的是显而易见的选择吗?
Cancer. 2024 Aug 1;130(15):2577-2581. doi: 10.1002/cncr.35350. Epub 2024 May 6.
8
Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.PD-1/PD-L1 抑制剂联合放疗治疗非小细胞肺癌患者的安全性和疗效:系统评价和荟萃分析。
Cancer Med. 2021 Feb;10(4):1222-1239. doi: 10.1002/cam4.3718. Epub 2021 Jan 19.
9
Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?肺癌的最佳一线免疫检查点抑制剂治疗:如何选择?
Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12.
10
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.携驱动基因突变的肺癌的免疫检查点阻断:择路需明智。
Am Soc Clin Oncol Educ Book. 2020 May;40:372-384. doi: 10.1200/EDBK_280795.

本文引用的文献

1
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review.非小细胞肺癌中的免疫检查点抑制剂:从当前视角到未来治疗——一项系统综述
Ann Transl Med. 2023 Aug 30;11(10):354. doi: 10.21037/atm-22-4218. Epub 2023 May 23.
2
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的 IB 期-IIIA 期非小细胞肺癌的辅助治疗(PEARLS/KEYNOTE-091):一项随机、三盲、III 期试验的中期分析。
Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.
3
Immunotherapy in non-small cell lung cancer: Past, present, and future directions.非小细胞肺癌的免疫疗法:过去、现在及未来方向
Front Oncol. 2022 Aug 2;12:877594. doi: 10.3389/fonc.2022.877594. eCollection 2022.
4
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
5
Updated Prognostic Factors in Localized NSCLC.局限性非小细胞肺癌的更新预后因素
Cancers (Basel). 2022 Mar 9;14(6):1400. doi: 10.3390/cancers14061400.
6
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.肺癌的免疫治疗:现状与未来方向。
Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022.
7
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.PACIFIC试验的五年生存结果:III期非小细胞肺癌放化疗后使用度伐利尤单抗治疗
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
8
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌(IMpower010):一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
9
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.培美曲塞联合铂类与或不联合帕博利珠单抗治疗未经治疗的转移性非鳞状非小细胞肺癌患者:KEYNOTE-189 的方案预设的最终分析。
Ann Oncol. 2021 Jul;32(7):881-895. doi: 10.1016/j.annonc.2021.04.008. Epub 2021 Apr 22.
10
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.西米普利单抗单药治疗 PD-L1 表达水平至少为 50%的晚期非小细胞肺癌的一线治疗:一项多中心、开放标签、全球、3 期、随机、对照临床试验。
Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2.